Transplantation for end-stage lung disease

Area of Science:

• Cardiothoracic Surgery
• Pulmonary Medicine
• Transplant Immunology

Background:

• Lung and heart-lung transplantation have evolved from experimental to established clinical treatments over the past decade.
• Advancements in surgical techniques and immunosuppression (cyclosporine) have broadened eligibility and improved outcomes for end-stage lung diseases.
• Improved organ preservation and donor procurement strategies have reduced peri-operative mortality.

Purpose of the Study:

• To review the advancements in lung and heart-lung transplantation.
• To highlight key innovations in surgical techniques, immunosuppression, and graft monitoring.
• To discuss persistent challenges, such as obliterative bronchiolitis, and future directions.

Main Methods:

• Review of recent literature on lung and heart-lung transplantation.
• Analysis of surgical innovations and immunosuppressive protocols.
• Discussion of diagnostic and monitoring techniques for graft health and complications.

Main Results:

• Successful transplantation is now feasible for a wider range of end-stage lung diseases.
• Reduced peri-operative mortality and improved organ procurement due to enhanced preservation techniques.
• Introduction of physiological monitoring and diagnostic tools for rejection and infection.

Conclusions:

• Lung and heart-lung transplantation are increasingly effective treatments for end-stage pulmonary disease.
• Obliterative bronchiolitis remains a significant challenge requiring further research in etiology, pathogenesis, and treatment.
• Transplantation research continues to yield valuable insights into pulmonary physiology and disease mechanisms.